Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 30, 2009

View Archived Issues

AVI BioPharma reports efficacy data from phase Ib/II clinical trial of AVI-4658 in DMD

Forest Laboratories to acquire additional rights to NXL-104 under agreement with Novexel

Novel DNA-binding compounds presented by CSIR

GlaxoSmithKline describes nAChR modulators as antipsychotic agents

Mitsubishi Tanabe Pharma discloses novel BK and maxi K+ channel openers

Cathepsin C inhibitors for the treatment of COPD identified by GlaxoSmithKline

Lilly identifies CB1 ligands for the treatment of obesity

New data indicate ridaforolimus-trastuzumab beneficial in refractory metastatic breast cancer

Compugen discovers drug target for treatment of epithelial tumors

Sinovac Biotech files application with SFDA for clinical trial of HFMD vaccine

SemBioSys Genetics presents update of its progress on Apo AI(Milano)

Tego Biosciences sells intellectual property to Luna Innovations

BTC induces apoptosis in PKCalpha overexpressing breast cancer cells

Glycemic control enhanced by adding alogliptin to insulin therapy in type 2 diabetes

Breast cancer growth inhibition seen with JMR-132 and tamoxifen

MVA-BN-HER2 well tolerated, active in phase I breast cancer studies

Tetrathiomolybdate may reduce endothelial progenitor cells in breast cancer patients

EMEA issues negative opinion on Cerepro for malignant brain cancer

Affomix to provide antibodies for Kalgene's diagnostics program

LifeCycle submits phase III protocol for LCP-Tacro trial to the FDA

Vical's phase III trial of Allovectin-7 receives positive safety review

Vivus submits NDA for Qnexa to FDA for treatment of obesity

Arigene terminates tender offer for Trimeris' outstanding shares of common stock

GSK identifies 5-HT2B receptor antagonists for fibrotic conditions and IBS

Gilead describes SCD inhibitors for the treatment of obesity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...